

Poster program

Tuesday, 23 September 2025

IMMU	IMMUNOSUPPRESSIVE DRUGS & BIOMARKERS						
Poster Board	Paper Title	Title	First Name	Last Name	Organization		
P500	Patient-centered design of immunosuppressant point-of-care tests for transplant recipients in remote settings		Kelsey	Leong	University of Washington		
P501	In-depth study of TDM data for tacrolimus in transplant patients	Dr	Wei-Jian	Ni	Anhui Provincial Hospital, The First Affiliated Hospital of USTC, University of Science and Technology of China		
P502	What gets measured gets managed: multiplex assay for mycophenolate monitoring	Dr	Meng	Wang	Vancouver Coastal Health		
P503	Model-informed precision dosing (MIPD) for tacrolimus in heart transplant recipients	A/Prof	Hong	Zhou	Department Of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology		

PHAR	PHARMACOGENETICS						
Poster Board	Paper Title	Title	First Name	Last Name	Organization		
P504	Association of TLR4 rs7873784 polymorphism with Tuberculosis susceptibility in healthy Thai population		Thanaporn	Chaturachumroenchai	Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand		
P505	Influence of ABCB1 rs1045642 Gene Polymorphism on prognosis of platinum-based chemotherapy	Dr	Yongwu	Chen	Anhui Provincial Hospital, The First Affiliated Hospital of the University of Science and Technology of China		
P506	NUDT15 polymorphism increases the risk of early neutropenia due to valganciclovir	Dr	Yurie	Katsube	Kyoto University Hospital		
P507	Genetic variants and Oxypurinol levels: Investigating Allopurinol response in gout	Dr	Shamin	Mohd Saffian	Universiti Kebangsaan Malaysia		
P508	Association between TLR-4 genetic variation and Tuberculosis susceptibility in Thai diabetic patients		Pornpawit	Phuangruankaew	Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand		
P509	Effect of recombinant CYP3A4 variants and interaction on imatinib metabolism in vitro	Dr	Ren-ai	Xu	First Affiliated Hospital of Wenzhou Medical University		



Tuesday, 23 September 2025

PHAR	MACOMETRICS				
Poster Board	Paper Title	Title	First Name	Last Name	Organization
P510	Individualising insulin bolus dosing in children diagnosed with type 1 diabetes mellitus	A/Prof	Hesham	Al-Sallami	College of Pharmacy, QU Health, Qatar University
P511	Lessons in real-time communication of potentially Erroneous data in MIPD software	Dr	Jordan	Brooks	InsightRX
P512	A new scoring methodology for implementation of POPPK models for TDM	Dr	Benedicte	Franck	Université de Rennes, CHU Rennes, Inserm, EHESP, IRSET- UMR S 1085. FHU SUPORT, Rennes, F-35000. Rennes, France
P513	Optimizing doxorubicin dosing in Asian patients with ABCB1*13 polymorphisms	Dr	Janice	Goh	Bioinformatics Institute, A*STAR
P514	Population pharmacokinetics of tacrolimus in renal transplant recipients combined with posaconazole	Dr	Nan	Hu	The Third Affiliated Hospital of Soochow University
P515	Incorporating metabolic transformation into pharmacokinetic models for Clozapine to improve dosage prediction	Prof	David	Joyce	PathWest Laboratory Medicine, Western Australia
P516	Propofol brain concentration during intraoperative awakening in awake craniotomy		Masayoshi	Kawata	Kyoto University Hospital
P517	Population pharmacokinetics of Cycloserine: A systematic review	Dr	Jinmeng	Li	Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, China
P518	Understanding inter-individual variability of lurasidone pharmacokinetics: a population model in Chinese patients	Prof	Meihua	Lin	The First Affiliated Hospital of Zhejiang University School of Medicine
P519	Comparison of 1-point and 2-point sampling for vancomycin Bayesian AUC estimation		Hirohito	Muroi	Kobe City Medical Center General Hospital
P520	Stochastic differential equations for modeling nonparametric inter-occasion variability (IOV) in pharmacokinetics (PK)	Prof	Michael	Neely	Children's Hospital Los Angeles, University of Southern California
P521	Evaluation of apixaban dose reduction algorithm based on creatinine clearance levels		Yuko	Shimamoto	National Cerebral and Cardiovascular Center
P522	A Scoping review of the paediatric population pharmacokinetic models of Morphine		Michael	Stokes	SCHN and University of Sydney
P523	Machine learning for Identifying factors of delayed methotrexate elimination in high-dose therapy	Dr	Kimitaka	Suetsugu	Department of Pharmacy Kagoshima University Hospital



Tuesday, 23 September 2025

Poster	N ONCOLOGY Paper Title	Title	First Name	Last Name	Organization
Board	Taper fille	TILLE	THSCINAING	Lastivarie	Organization
P524	Formulation and evaluation of capecitabine embedded self-dissolving microneedle in breast cancer		Krishnalekha	Bandyopadhyay	JSS College Of Pharmacy, Mysuru, JSSAHER, Karnataka India
P525	Busulfan limited sampling strategy evaluation in pediatric HSCT patients using Bayesian CDSS		Othmar	Korn	DoseMe Pty Ltd
P526	The application of aptamer-based sensor in point-of-care therapeutic drug monitoring	Dr	Lixian	Li	Chongqing University Cancer Hospital
P527	The relationship between sunitinib exposure and toxicity in real-world patient with mRCC		Qiaoqiao	Li	Chongqing University Cancer Hospital
P528	Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes	Dr	Wenjuan	Miao	Institute Of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
P529	Clinical significance of measuring free lenvatinib concentrations in patients with hepatocellular carcinoma		Ken	Shiraiwa	Oita University Hospital
P530	Exploring novel therapeutic strategies for Cholangiocarcinoma using cell culture models		Thanyarat	Srichainan	Srinakharinwirot University
P531	Deconjugation of methotrexate polyglutamates to methotrexate monoglutamate for therapeutic drug monitoring		Janani	Sundaresan	Laboratory Specialized Diagnostics & Research, Department of Laboratory Medicine, Amsterdam University Medical Center,
P532	Review of 2 and 3 points of Busulfan monitoring, which is accurate?	Assist Prof	Karunrat	Tewthanom	Silpakorn University
P533	Inhibitory effects of dihydropyridine drugs on tamoxifen metabolism and molecular docking	Dr	Ren-ai	Xu	First Affiliated Hospital of Wenzhou Medical University